Mepivacaina Recordati (Mepivacaine Hydrochloride)

Mepivacaine works by reversibly blocking voltage‑gated sodium channels on neuronal membranes. This inhibition prevents the rapid influx of sodium ions needed for depolarisation, thereby stopping the initiation and propagation of nerve impulses and producing a temporary loss of sensation in the targeted area.

The appropriate dose of Mepivacaina Recordati is determined by the prescribing clinician based on the specific procedure, patient characteristics, and route of administration. Dosage must be individualized and follows local regulatory and clinical guidelines.

Safety data for mepivacaine during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Mepivacaine is an amide‑type local anesthetic with a rapid onset and intermediate duration, similar to lidocaine but with slightly longer analgesic effect and less vasodilatory activity. This can reduce the need for vasoconstrictors in certain procedures, making it a useful alternative when a longer block is desired.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from direct light, moisture and extreme temperature fluctuations. Ensure the container is sealed when not in use and keep it out of reach of children.

Mepivacaina Recordati is supplied as a sterile solution for injection. It is administered by a qualified healthcare professional via epidural, infiltration or perineural routes, depending on the clinical indication. Proper aseptic technique and dosage calculation are essential for safe use.

Serious risks include cardiovascular toxicity such as arrhythmias, central nervous system toxicity leading to seizures, and severe allergic reactions including anaphylaxis. Prompt recognition and management of these events are critical, and patients should be monitored closely during and after administration.

Patients with known hypersensitivity to mepivacaine, other amide‑type local anesthetics, or any component of the formulation should avoid its use. Caution is also advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking interacting medications as listed in the interaction section.